COLD BLOODED MURDERERS –

JANUARY 23, 2020 – Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.comT&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here. https://www.ft.com/insys

He described his thinking: “Not only is the company going to get fined an astronomical amount of money, which I’ve seen a million times, but worse case scenario, which I’ve never seen before, they might actually take my money.” … Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.comT&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here. 

Subsys was approved for cancer patients already taking opioids who were experiencing the sharp pangs of what is called breakthrough pain. But the vast majority of doctors Insys targeted were not oncologists.  Mr Burlakoff said that no one at the company cared whether the doctors were prescribing it “on-label” for cancer patients or “off-label” for anyone else. If Insys had just stuck to cancer patients, he said, “you never would have heard of the company”.

@FinancialTimes